CVKD
Cadrenal Therapeutics, Inc.Company with tickers: CVKD
CIK
1937993
CUSIP
127636207
Shares Outstanding
2,868,247
Website
https://www.cadrenal.com
Investor Relations
https://www.cadrenal.com/investors/
13F Activity (30d)
2 filings
1 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Quang X. Pham | interim Principal Accounting Officer | Appointed | 2026-06-03 |
| Quang X. Pham | interim Chief Financial Officer | Appointed | 2026-06-03 |
| Matthew K. Szot | Chief Financial Officer | Terminated | 2026-06-03 |